

# Christine Gennigens MD



## Christine Gennigens MD

PROFESSOR

Gynecological and Genito-Urinary Cancer Specialist

Head of clinics at University Hospital Center (CHU) of Liège, and researcher of clinical trials. She is currently involved in the daily clinical management of patients with solid tumors, focusing particularly on genitourinary, gynecological, sarcoma and rare tumors. She has more than 30 scientific publications as author and co-author.

**Full name:** Christine Gennigens.

**Country:** Belgium

**Current Position:**

2014-present	Member of the medical board. CHU of Liège. Belgium.
2008-present	Principal investigator and sub-investigator of several trials phase 1, 2 and 3 at experimental research unit in medical oncology. CHU of Liège. Belgium.
2005-present	Head of clinics. CHU of Liège. Belgium.

**Education:**

2005	Specialist in internal medicine and medical oncology. University of Liège (ULg). Belgium.
2000	Doctor in medicine. ULg. Belgium.

**Experience:**

2014-present	Member of the medical board. CHU of Liège. Belgium.
2008-present	Principal investigator and sub-investigator of several trials phase 1, 2 and 3 at experimental research unit in medical oncology. CHU of Liège. Belgium.
2005-present	Head of clinics. CHU of Liège. Belgium.

**Scientific publications**

Number of publications as author or co-author: 36

Abstracts / posters: 8

Recent scientific publications:

Carcinoma of unknown primary: a not so rare entity. Gonne E., Collignon J., Jerusalem G., Gennigens C. Rev Med Liège. 2016 Oct; 71 (10): 449-454.

Adipsic diabetes insipidus revealing a bifocal intracranial germinoma. Kreutz J, Potorac I, Lutteri L, Gennigens C, Martin D, Daly Af, Bonneville Jf, Tshibanda L, Beckers A. Ann Endocrinol. 2017 May;5.pii: S0003-4266 (17) 30023-9.

A Phase IIa Study of Tisotumab Vedotin (HuMax®-TF-ADC) in Patients With Relapsed, Recurrent and/or Metastatic Cervical Cancer Vergote I, Concin N, Dean E, Lassen U, De Bono JS, Drew Y, Machiels JP, Nielsen D, Arkenau T, Forster M, Jones R, Slomovitz B, Spicer J, Johnson M, Cornez N, GENNIGENS C, Fulton B, Basse L, Lisby S, Coleman R, Hong DS ESMO 2017- oral abstract presentation.

Phase IIa Study of Tisotumab Vedotin (HuMax®-TF-ADC) in Patients With Relapsed, Recurrent and/or Metastatic Cervical Cancer: Updated Safety and Efficacy. N. Concin, I. Vergote, E. Dean, U. Lassen, Y. Drew, J.P. Machiels, D. Nielsen, T. Arkenau, M. Forster, R. Jones, B. Slomovitz, J. Spicer, M. Johnsson, N. Cornez, C. Gennigens, B. Fulton, R. Rangwala, R. Coleman, D. Hong. ESGO 2017-e-poster.